| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 119.61% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 09/15/2023 | 49.02% | JP Morgan | $16 → $19 | Maintains | Overweight |
| 09/06/2023 | 64.71% | Oppenheimer | → $21 | Reiterates | Outperform → Outperform |
| 09/05/2023 | 119.61% | HC Wainwright & Co. | $22 → $28 | Maintains | Buy |
| 08/10/2023 | 25.49% | JP Morgan | $14 → $16 | Maintains | Overweight |
| 08/09/2023 | 41.18% | Credit Suisse | $16 → $18 | Maintains | Outperform |
| 08/09/2023 | 72.55% | HC Wainwright & Co. | $17 → $22 | Maintains | Buy |
| 07/21/2023 | 64.71% | Oppenheimer | → $21 | Initiates Coverage On | → Outperform |
| 05/11/2023 | 33.33% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 03/10/2023 | -13.73% | Credit Suisse | $12 → $11 | Maintains | Outperform |
| 03/10/2023 | 17.65% | HC Wainwright & Co. | $12 → $15 | Maintains | Buy |
| 02/22/2023 | -5.88% | Credit Suisse | → $12 | Initiates Coverage On | → Outperform |
| 07/06/2022 | 25.49% | Canaccord Genuity | → $16 | Assumes | → Buy |
| 06/10/2022 | — | HC Wainwright & Co. | Upgrades | Neutral → Buy | |
| 02/28/2022 | — | HC Wainwright & Co. | Initiates Coverage On | → Neutral | |
| 12/14/2020 | 370.59% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
What is the target price for Olema Pharmaceuticals (OLMA)?
The latest price target for Olema Pharmaceuticals (NASDAQ: OLMA) was reported by HC Wainwright & Co. on October 11, 2023. The analyst firm set a price target for $28.00 expecting OLMA to rise to within 12 months (a possible 119.61% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Olema Pharmaceuticals (OLMA)?
The latest analyst rating for Olema Pharmaceuticals (NASDAQ: OLMA) was provided by HC Wainwright & Co., and Olema Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Olema Pharmaceuticals (OLMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Olema Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Olema Pharmaceuticals was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
Is the Analyst Rating Olema Pharmaceuticals (OLMA) correct?
While ratings are subjective and will change, the latest Olema Pharmaceuticals (OLMA) rating was a reiterated with a price target of $0.00 to $28.00. The current price Olema Pharmaceuticals (OLMA) is trading at is $12.75, which is within the analyst's predicted range.